Ricki Kumar
Critical Care Medicine · Grand Junction, CONPI 1548794761
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $499 of the $616 with a category attached, or 80.9%. 8 manufacturers reported payments, led by Grifols USA, LLC at 28.8% of the total. Reporting peaked in 2019 at $225 and has fallen 85.7% since, to $32 in 2025.
Across 14 payments — averaging $44.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$177
- Actelion Pharmaceuticals US, Inc.$125
- Boehringer Ingelheim$125
- Genentech USA, Inc.$100
- AbbVie$48
- Insmed, Inc.$17
- plus $23 from 2 others
What the payments were for
- Food & beverage$49981%
- Education$11719%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 6 | $177 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Boehringer Ingelheim | 1 | $125 |
| Genentech USA, Inc. | 1 | $100 |
| AbbVie | 2 | $48 |
| Insmed, Inc. | 1 | $17 |
| AstraZeneca | 1 | $15 |
| United Therapeutics Corporation | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$616 in reported general payments places this provider in the 60th percentile of 141 critical care medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 23 | $457 |
| Montelukast Sodium | 13 | $143 |
| Azithromycin | 11 | $75 |
| Prednisone | 25 | $52 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Grand Junction
- Mark McGinleyGrand Junction$905
- Peter HountrasAurora$86K
- Paul WischmeyerAurora$78K
- Chakradhar KotaruGreenwood Village$61K
- Gregory CosgroveDenver$46K
- Walter ConwellDenver$42K
- David HsiaDenver$38K
- Nitin GuptaLittleton$35K
- Paula McDermottLittleton$34K
- Jennifer Faber GerlingDenver$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.